Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the ...

Bernard Fontana, France's nominee to head state nuclear company EDF, would face a daunting to-do list if he gets the job, ...

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk ...

Cooper Flagg #2 of the Duke Blue Devils defends Jason Asemota #5 of the Baylor Bears during the second round of the 2025 NCAA ...

The "Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035 -- Distribution by Type of Device, Route ...

R&D innovation is likely to remain a major focus area in 2025 . M&A activity is also expected to remain strong, particularly with Trump’s return to the White House.Regular pipeline setbacks, slow ramp ...

The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. | The ...

A leading U.S.-based drug delivery device company known for its strong global commercial presence recognized this opportunity ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

A new search tool unveiled Friday increases public access to information about the connections between advisors to the ...